State of New Jersey Common Pension Fund D Has $1.89 Million Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

State of New Jersey Common Pension Fund D trimmed its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 13.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 42,593 shares of the biopharmaceutical company’s stock after selling 6,350 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Agios Pharmaceuticals were worth $1,892,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of AGIO. Acadian Asset Management LLC bought a new stake in Agios Pharmaceuticals in the second quarter valued at $37,000. Quest Partners LLC acquired a new stake in shares of Agios Pharmaceuticals in the 2nd quarter valued at $40,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Agios Pharmaceuticals by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 363 shares during the last quarter. CWM LLC increased its position in shares of Agios Pharmaceuticals by 554.7% during the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $96,000 after purchasing an additional 1,836 shares in the last quarter. Finally, North Star Asset Management Inc. bought a new position in Agios Pharmaceuticals during the 2nd quarter valued at about $216,000.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on AGIO shares. StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. Leerink Partnrs cut Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Friday, September 20th. Raymond James restated an “outperform” rating and issued a $51.00 target price on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Finally, Leerink Partners downgraded shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $60.00 to $56.00 in a research report on Friday, September 27th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $52.33.

Insider Buying and Selling

In related news, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the sale, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at $988,346.74. The trade was a 11.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.93% of the stock is currently owned by insiders.

Agios Pharmaceuticals Trading Down 1.7 %

Shares of NASDAQ:AGIO opened at $52.89 on Tuesday. Agios Pharmaceuticals, Inc. has a 1-year low of $20.96 and a 1-year high of $62.58. The stock has a market capitalization of $3.02 billion, a P/E ratio of 4.66 and a beta of 0.75. The business has a 50-day moving average price of $46.62 and a two-hundred day moving average price of $44.07.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.